What Is KLOW Peptide? The Four-Component Blend Explained

KLOW is not a peptide. It is a name given to a four-component research blend supplied as a single 80 mg lyophilized vial, and the distinction matters more than it first appears. Searching the name returns product listings rather than literature, because no paper describes KLOW: the published research covers each of its four components separately, studied on their own. This page explains what the name refers to, where the term came from, and what can and cannot be said about the blend as sold.

What does KLOW stand for?

It is an informal acronym assembled from the four peptides in the vial:

• KPV, a tripeptide corresponding to the C-terminal sequence of a larger signalling molecule
• GHK-Cu, a copper-binding tripeptide, and the component that gives the powder its colour
• BPC-157, a 15-amino-acid synthetic peptide
• TB-500, a synthetic fragment of thymosin beta-4

The letters are a market convention rather than a registered designation, which is the most important fact about the name.

An approved drug has a composition fixed by a registered specification. Every batch must meet it, and no manufacturer can redefine it. KLOW has no such document behind it. Nothing prevents two suppliers from selling vials labeled KLOW 80 mg with the four components divided differently, and nothing obliges either to publish the division. The name describes a category that the research-supply market converged on, not a standard, and the only binding description of any particular vial is the certificate of analysis issued for that lot.

That is why the blend is usually written out as its four components on a listing. The expanded form is the specification; the four-letter name is shorthand.

Why is KLOW blue?

One of the four components is a copper complex, and copper-bound peptides carry colour. Most lyophilized peptides are a white to off-white powder. A KLOW vial is blue-tinted, sometimes quite distinctly, and the shade varies with fill volume, how the material settled during freeze-drying, and the light you view it in.

That colour is a weak positive signal. It indicates that the copper-containing component is present in the vial. It does not indicate how much, and it cannot be used to judge the ratio between components or the quality of the other three. A pale vial and a deeply blue vial can both be correct, and a correctly blue vial can still be short on a component the colour says nothing about. Colour is a first look, not a test.

What does the research actually cover?

Each component separately, and none of them as this blend.

The repair-associated peptide most associated with the blend has an extensive preclinical record and very little else. A 2025 systematic review in HSS Journal searched PubMed, Cochrane and Embase from database inception to June 3, 2024, screened 544 articles published between 1993 and 2024, and after removing duplicates included 36 studies: 35 preclinical and 1 clinical (PMID 40756949). That ratio is the honest summary of where the evidence sits.

The copper-containing component has the longest history of the four. It is a small naturally occurring tripeptide present in human plasma that can also be released from tissue after injury, and a 2018 review in the International Journal of Molecular Sciences describes work on its effects on tissue repair and on gene-expression pathways (PMID 29986520). An earlier review in BioMed Research International covers its role as a modulator of cellular pathways in skin regeneration (PMID 26236730).

The smallest component is a tripeptide corresponding to the C-terminal sequence of a larger signalling molecule. The primary mechanistic work is a 2008 study in Gastroenterology showing it is taken into cells through the PepT1 di- and tripeptide transporter, with effects on inflammatory signalling demonstrated in intestinal epithelial cells, immune cells and rodent colitis models (PMID 18061177). The evidence base there is cell-model and rodent work.

The fourth is a fragment of thymosin beta-4, an actin-sequestering molecule found in most cells. A 2005 review in Trends in Molecular Medicine describes its biochemical properties and its role in dermal and corneal wound healing (PMID 16099219).

Then the gap. No published study has evaluated these four together as the blend sold under this name. There is no combination trial, no interaction data between the components, and no published rationale establishing that the market-standard ratio is the right one. Listings that summarise each component’s individual research are describing four separate literatures and leaving the reader to assume the blend inherits all of them. It does not follow, and the absence of blend-level data is itself the most useful thing to know about KLOW.

How is a blend different from a single peptide in practice?

In three ways that matter before purchase.

Documentation is harder. A single-peptide certificate answers one question about identity and one about purity. A four-component certificate has to identify each component, report purity, and account for the ratio between them, and the ratio check is the one most often missing. A single high purity figure on a blend vial tells you the contents are peptide rather than contaminant; it does not tell you the four are present in the stated proportions.

The ratio is fixed. Buying four single vials gives you control over how much of each you hold, and four separate certificates. Buying the blend gives you one vial, one document and a fixed division decided by the supplier.

Comparison by price is unreliable. Per-mg cost on a blend divides the price by total blend mass, which spans four components of very different individual value, so the figure is not comparable to a single-peptide per-mg price or between blends with different splits. The pricing arithmetic, and what to check before comparing two listings, is worked through in the KLOW price and buying guide.

How does KLOW compare with GLOW?

GLOW is the same family of blend with one fewer component. Both are informal names for co-lyophilized research preparations, both are supplied as a single vial, and both carry the same blue tint from their copper component. The practical difference is the component count, and therefore what a certificate has to account for and how the total mass is divided.

Neither name is defined by a standards body, so the caution that applies to KLOW applies equally to GLOW: the list of components is a description, and the certificate for the specific lot is the only binding statement of what is in the vial.

Common questions about KLOW peptide

Is KLOW a single peptide? No. It is four peptides co-lyophilized into one vial and sold under one name.

Is KLOW approved for anything? No. None of the four components holds marketing approval as a blend, and KLOW itself is a research-supply designation rather than a medicine. It is supplied for laboratory research use only, not for human consumption.

How many milligrams are in a KLOW vial? The market-standard size is 80 mg of total blend material. How that 80 mg is divided between the four components is set by the supplier and should be stated on the certificate of analysis.

Has KLOW been studied as a blend? No published study has evaluated the four components together in this combination. The available research covers each component individually.

Where does the name come from? It is an informal acronym built from the four component names, used across the research-supply market rather than defined by any standards body.